GTHライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 3月 2024 @ 05:00):

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment...

Stats
本日の出来高	412 603
平均出来高	51 864.00
時価総額	127.29M
EPS	$0 ( 2024-01-18 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.110
ATR14	$0.00400 (0.10%)

Genetron Holdings Limited 相関

10 最も正の相関
CLGN	0.946
RING	0.916
IGLD	0.899
ORIC	0.87
USAU	0.865
SSRM	0.864
BTAI	0.858
DOOO	0.857
ISHG	0.857
SLQD	0.854

10 最も負の相関
HQY	-0.854
RCMT	-0.843
CRSA	-0.832
LNSR	-0.82

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Genetron Holdings Limited 財務諸表

Annual	2022
収益:	$650.71M
総利益:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2022
収益:	$650.71M
総利益:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2021
収益:	$531.95M
総利益:	$337.97M (63.53 %)
EPS:	$-4.73

FY	2020
収益:	$424.49M
総利益:	$260.22M (61.30 %)
EPS:	$-50.90

Financial Reports:

No articles found.

Genetron Holdings Limited

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.